Details

Published: 01 May 2026

Hits: 44

It looks like a travel shampoo bottle, smells like bubblegum, and fits in a school bag pocket. On top of that, it costs less than a coffee. And according to a growing and convergent body of scientific research, it is very likely giving young people cancer. The vaping carcinogens inhaled with every puff are no longer a theoretical concern or a precautionary footnote. They are the documented conclusion of some of the most rigorous independent research conducted on e-cigarettes to date, and that conclusion demands a response that matches its urgency.

We have been here before. The parallels are not subtle.

The Same Story, Running Again

It took nearly a century, from the mid-1800s to the landmark US Surgeon General’s report in 1964, for smoking to be officially recognised as a cause of lung cancer. During those decades, early warning signs were dismissed, industry interests were advanced over public health, and generations of people paid the price with their lives. Researchers at UNSW Sydney, who led the most comprehensive review of e-cigarette carcinogenicity yet published, have drawn that parallel directly. Their message is unambiguous: “E-cigarettes were introduced about 20 years ago. We should not wait another 80 years to decide what to do.”

That review, published in the journal Carcinogenesis in March 2026 and led by Adjunct Professor Bernard Stewart AM, brought together experts in pharmacology, epidemiology, thoracic surgery and public health from UNSW, the University of Queensland, Flinders University, the University of Sydney and multiple major hospitals. Their conclusion, drawn from clinical monitoring, animal studies and laboratory research, was unequivocal: nicotine-based e-cigarettes are likely to cause lung cancer and oral cancer in people who use them.

“To our knowledge, this review is the most definitive determination that those who vape are at increased risk of cancer compared to those who don’t,” said Professor Stewart.

What Is Actually Being Inhaled

The marketing of e-cigarettes has always emphasised what they are not: not tobacco, not combustion and, by implication, not particularly dangerous. The science, however, tells a very different story about the vaping carcinogens concealed inside every device.

A 2025 study from the University of California, Davis tested seven types of disposable e-cigarettes from three of the most popular brands on the market. Researchers created between 500 and 1,500 puffs for each device and measured the metal concentrations in the resulting vapour. What they found stopped the lead researcher mid-analysis. “When I first saw the lead concentrations, they were so high I thought our instrument was broken,” said PhD candidate Mark Salazar.

They were not broken. One disposable e-cigarette released more lead during a single day’s use than nearly 20 packs of traditional cigarettes. Levels of chromium, nickel and antimony increased as puffing continued. Leaded bronze alloy components were leaching nickel and lead directly into the e-liquid. Heating coils were releasing additional nickel. Antimony, a known carcinogen, was present in unused e-liquids at high concentrations before a single puff had been taken.

Three of the seven devices had nickel levels in their vapour that exceeded cancer risk limits. Two had antimony levels above the same threshold. Four produced vapour with nickel and lead emissions surpassing health-risk limits for neurological damage and respiratory disease, not just cancer.

These are not obscure chemicals. Lead exposure in young people causes irreversible neurological damage. Nickel and antimony are known carcinogens. Chromium compounds at elevated concentrations are associated with lung cancer. They are not the ingredients of a harm-reduction device. They are the contents of a product being sold to teenagers outside school gates across Australia.

The Cancer Pathway

The UNSW-led review in Carcinogenesis examined how vaping carcinogens drive cancer risk at a biological level, drawing on biomarker studies, animal experiments and mechanistic laboratory research. The findings across all three categories pointed in the same direction.

In human biomarker studies, researchers identified DNA damage correlated with vape-derived metabolites from carcinogens including nicotine-derived nitrosamines, volatile organic compounds, flavour-derived agents and metals. Vaping-attributable oxidative stress, epigenetic change and inflammation were found in oral and respiratory tissue. In animal experiments, inhalation exposure to e-cigarette aerosol caused lung adenocarcinomas in mice. Mechanistic data, analysed using the key characteristics of carcinogens, pointed to a complex chemical mixture causing cancer via both genotoxic and other biological processes.

The evidence, as co-author Associate Professor Freddy Sitas put it, “was remarkably consistent across fields.” E-cigarette carcinogenicity is not a single study’s finding. It is the convergent conclusion of multiple disciplines of investigation, reviewed across an eight-year period from 2017 to 2025.

The Dual-Use Trap

Vaping was introduced and marketed, in Australia and internationally, as a tool for quitting smoking. The Australian government’s 2023 regulations reflect this framing: disposable vapes are banned, while therapeutic vapes may be sold only in pharmacies and only to support smoking cessation. It is a reasonable regulatory position. The problem is that it does not match what is actually happening.

Most people who use e-cigarettes to quit smoking do not quit. Instead, according to A/Prof. Sitas, they end up in what he describes as “dual-use limbo”, unable to stop smoking and unable to stop vaping, now carrying both habits simultaneously. Epidemiological data from the United States shows that people who both vape and smoke are at a four-fold increased risk of developing lung cancer compared to those who only smoke. The device sold as a solution is, for many, compounding the problem.

The reach of vaping carcinogens into the youngest cohorts makes this more alarming still. Most consumers of disposable e-cigarettes, the very devices found to emit the highest concentrations of toxic metals, are teenagers and young adults. These are the people whose neurological systems are most susceptible to lead exposure, whose lung tissue is still developing, and who are being reached by a product that smells like bubblegum, comes in hundreds of varieties and remains widely accessible despite its illegal status in Australia.

The Market Outrunning the Science

The UC Davis researchers made a point that should be impossible to overlook. The market for disposable e-cigarettes is outpacing the science. Few studies of the relatively new devices are available. Consumers and regulators are largely uninformed. The nearly 100 disposable e-cigarette brands currently on the market have not been systematically tested. The seven devices studied by UC Davis represent a fraction of what is being sold, carried and inhaled, including by children who have never smoked a cigarette in their lives.

E-cigarette carcinogenicity research, as the Carcinogenesis review makes clear, has moved over eight years from calling for more evidence to issuing firm warnings. The science has done its job. The question now is whether the response, regulatory, social and institutional, will move at the pace the evidence demands, or whether it will take another generation and another body count before the message lands.

Smoking killed millions while the world waited for certainty. The bubblegum-flavoured version of that story is already in progress. The vaping carcinogens are identified. The cancer pathway is documented. The evidence does not require more time. It requires action.

(Source: WRD News)

Details

Published: 30 April 2026

Hits: 129

Scientists in Israel have just engineered a tobacco plant to grow five psychedelic drugs at once. They call it pharmaceutical progress. They call it a simpler, more sustainable route to medicine. Yet what they have actually built, beneath the language of research and therapeutic potential, is a more efficient delivery system for psychotropic compounds that have already demonstrated, repeatedly and on the record, that they harm people. This is where psychedelic drug research has arrived. Not at a cure. At a crop.

The five compounds produced by the modified tobacco plant are psilocybin and psilocin, found in magic mushrooms; DMT, extracted from various plants; and bufotenin and 5-methoxy-DMT, secreted by the Colorado river toad. Using a technique called agroinfiltration, researcher Asaph Aharoni and his team at the Weizmann Institute introduced nine foreign genes into a single tobacco plant and produced all five simultaneously. Furthermore, Aharoni confirmed that the same process could be applied to tomato, potato and corn.

He chose not to make the modification permanent. When asked why, he said it would be “a little bit tricky” because people would ask for seeds.

Read that again. The lead scientist on a project that others present as medical advancement describes his primary reason for restraint as the inconvenience of people asking for seeds. This is not pharmaceutical development. Instead, this is cultivation of some of the most powerful mind-altering substances on earth, with a voluntary handbrake that nobody is required to keep applied.

What the Evidence Actually Says

Before researchers harvest a single tobacco plant, it is worth asking what the therapeutic case for these compounds actually looks like. Because psychedelic drug research has been telling the same story for years: breakthrough treatment, revolutionary potential, the dawn of a new era in mental health. Yet the evidence has never caught up with the narrative.

Notably, the largest comparison trial of psilocybin ever conducted enrolled just 59 people. Earlier studies ran on 12 to 27 participants, some with no control group at all. These are not the foundations of proven medicine. Rather, they are the foundations of a billion-dollar industry that decided momentum was more important than proof.

The conflicts of interest run deep. One leading psychedelic drug researcher acknowledged knowing only a single colleague who had never personally used the drugs being studied. Moreover, financial ties between researchers and the psychedelic companies funding them appear disclosed in paper after paper. The field has a term for this kind of research: “me-search.” Research that finds what it was always going to find because the people running it already believe the answer.

Although the surge of investment and media attention surrounding psychedelic-assisted therapy has been enormous, the quality of the science has not kept pace. Growing scepticism has been building within the scientific community itself, not from outside critics, but from researchers who have looked closely at the evidence and found it wanting. It has simply attracted more investment and more media attention.

The Brain Studies Say “Shaky Ground”

In April 2026, researchers published the most comprehensive study of psychedelic drugs and the brain ever conducted in Nature Medicine. The study drew on more than 500 brain scans, 267 participants, eleven independent studies, and five substances, including three of the five now grown in an Israeli greenhouse. Researchers found that all five flatten the brain’s natural processing hierarchy, dissolving the organised structure through which the brain normally functions and producing what they called “unleashed cross-talk between brain systems.”

Journalists widely reported this as a landmark finding. However, what received far less coverage was what the study’s senior author said about the state of his own field: “This field is emerging, and it is very important, but they are on shaky ground.”

Additionally, the study’s own rigorous modelling found that earlier, smaller studies claiming widespread brain disintegration under psychedelics did not hold up. For context, the DMT dataset, covering one of the five compounds now cultivated in that tobacco plant, comprised only 16 participants. The ayahuasca dataset comprised just nine. Yet these are the numbers researchers use to justify scaling production.

Shaky ground is not a metaphor here. It is the senior researcher’s own description. Consequently, the response from the laboratory is to build a greenhouse.

The Placebo Problem Nobody Wants to Name

A fundamental flaw sits at the heart of psychedelic-assisted therapy trials that the industry does not advertise. Researchers cannot blind these studies. Participants always know whether they have taken a psychedelic drug, because the effects are unmistakable. As a result, every trial result carries contamination by expectation. People who believe they receive a powerful treatment often feel better simply because they believe it. People who realise they received a placebo sometimes deteriorate sharply from the disappointment.

Researchers at the University of Auckland and King’s College London have both published work on this problem. Their conclusion is stark: the large differences between treatment and placebo groups in psychedelic drug research trials likely measure more than just improvement in the treated group. In fact, they also measure deterioration in the placebo group. Consequently, the results are inflated, and the industry is overstating the effectiveness of these drugs. Meanwhile, the tobacco plant is being engineered to grow more of them.

The People Nobody Mentions

Behind all the trial data and the brain scans and the greenhouse engineering, there are people. They tend not to appear in the press releases.

Kate Hyatt was 32 years old. In June 2021 she attended a plant medicine retreat in Worcestershire and took a powerful hallucinogen. Three months later she described a psychotic break so severe she felt her brain was going to explode. That autumn she took her own life. The coroner linked her deteriorating symptoms to the hallucinogens she had consumed. She had gone looking for help with her mental health. The psychedelic-assisted therapy movement gave her something that destroyed it.

She is not alone. A Compass Pathways clinical trial of psilocybin for treatment-resistant depression reported that three participants showed suicidal behaviour lasting at least a month after receiving the drug. Furthermore, a 21-year-old woman who self-medicated with a high dose of psilocybin to treat her own depression walked to the middle of the Golden Gate Bridge and jumped. In MAPS-sponsored MDMA therapy trials, footage emerged of therapists restraining a patient, gagging her and lying on top of her while she was under the influence of the compound. The lead therapist later admitted to having sex with her while she remained enrolled in the trial.

These are not aberrations. Rather, they are the logical consequence of administering compounds that, by the admission of researchers in the field, make users “pliant and suggestible.” When a substance dissolves the brain’s normal defences and places a vulnerable person in the hands of anyone with less-than-honourable intentions, the outcome is not always therapeutic. Sometimes it is devastating. No tobacco plant, however efficiently engineered, changes that pharmacological reality.

Science Racing Ahead of Ethical Reckoning

There is a word for what happens when scientific capability races ahead of ethical reckoning. The Weizmann Institute has demonstrated that five psychotropic compounds can grow in a single crop, at agricultural scale, using a process transferable to the most common food plants on earth. They have done this in a field where the therapeutic evidence sits on shaky ground by the admission of its own senior researchers, where documented harms include deaths, suicidal behaviour within clinical trials and sexual abuse within supervised therapy sessions, and where a scientist’s reluctance to deal with seed requests stands as the primary restraint against open distribution.

The creature, to borrow Mary Shelley’s framing, is not being built because medicine needs it. Instead, the laboratory builds it because the capital is there, and because a field that has never allowed evidence to slow its momentum now has a cultivation method that grows in soil, requires no pharmaceutical supply chain and can scale without limit.

Rupert Fray at the University of Nottingham called it a valuable technical accomplishment and spoke of “green factories” growing compounds in greenhouses. He is right about the factories. However, the question his framing avoids is what these factories are actually producing, and for whom.

This Is Not Medicine. This Is Access.

Psychedelic drug research has not yet established what these compounds treat, in whom they are safe, at what dose, under what supervision or with what long-term consequences. Its own most rigorous brain study describes its foundations as shaky. Its own researchers acknowledge the conflicts of interest. Moreover, its own clinical trials have produced documented suicidal behaviour and enabled abuse.

What it has established, reliably and at scale, is an appetite. An appetite in an industry, in a media cycle and in a culture that has decided these substances are the next frontier, and that the science can catch up later. Therefore, the tobacco plant is not the beginning of responsible pharmaceutical development. It is the next step in a process that has never been primarily about medicine.

The lead researcher noted that people will ask for seeds. He is correct. They will. And when they do, the question of whether psychedelic drug research ever delivered on its therapeutic promise will feel very distant from the reality of what was grown, and where it ended up.

(Source: WRD News)

Details

Published: 18 April 2026

Hits: 96

A landmark study published in the journal Brain has confirmed that regular ‘recreational’ use of MDMA, commonly known as ecstasy, causes measurable MDMA brain damage. Scientists found that the drug shrinks key memory regions and that the damage worsens the more a person uses it.

The research involved 122 participants across the University of Zurich. It is among the most thorough investigations to date into what ecstasy does to the human brain structurally. Its findings paint a sobering picture for anyone who considers recreational use low risk.

What the Study Found About MDMA Brain Damage

Researchers compared 61 regular MDMA users with 61 matched controls who had never used the drug. Each participant had detailed MRI brain scans and completed a series of verbal memory tests.

The results were striking. MDMA users had significantly reduced grey matter volume in the hippocampus, the brain’s primary hub for forming and storing memories. The loss centred on the CA1 and CA2/3 subregions, which are critical for verbal learning and long-term recall.

The memory test scores told the same story. MDMA users performed notably worse across four key measures:

• Learning performance scored significantly lower
• Recall after interference showed a marked decline
• Long-term delayed recall dropped considerably
• Recognition accuracy fell well below the control group

Only supraspan, a measure of immediate memory capacity, showed no significant difference between the two groups.

The More You Use, the Worse the Ecstasy Memory Loss

One of the study’s most valuable contributions was linking the extent of brain damage directly to consumption levels. Researchers used hair toxicology tests, which provide an objective record of drug intake over the previous three to four months. They found a clear pattern: the higher the MDMA concentration in a person’s hair, the smaller their hippocampal CA1 volume.

Self-reported MDMA use in the previous six months also predicted worse scores across learning, interference recall and long-term recall. No other substance in the study produced the same pattern. Alcohol, cannabis, cocaine and amphetamine all came up short, even though MDMA users consumed more of those substances than controls did.

That dose-response relationship is significant. It strongly suggests the cognitive deficits stem from MDMA specifically, not from general drug use. The evidence points squarely at ecstasy.

A Serotonin System Under Attack

MDMA brain damage does not strike at random. The study correlated the regions of structural brain change with published brain maps showing where serotonin receptors concentrate most densely.

The pattern held up consistently. The brain regions showing the greatest grey matter loss in MDMA users were the same regions richest in 5-HT1A, 5-HT2A and 5-HT4 serotonin receptors.

This finding matters because MDMA works by flooding the brain with serotonin. That flood produces the drug’s well-known feelings of euphoria and warmth in the short term. Over time, however, it appears to degrade the serotonergic architecture of the brain, especially in receptor-dense areas.

The study authors noted that grey matter differences between groups aligned closely with 5-HT1A, 5-HT2A and 5-HT4 receptor density maps, pointing to a serotonergic basis for both the memory problems and the structural changes.

One finding stood out. The serotonin transporter (SERT), a long-studied marker in ecstasy memory loss research, did not correlate with grey matter changes here. Other research has shown SERT levels can recover with abstinence while memory deficits remain. That suggests something more permanent may be happening at a structural level.

Why MDMA Brain Damage Matters Beyond the Lab

The hippocampus is not just another brain region. It sits at the centre of our ability to learn new information, navigate our surroundings and recall life events. Doctors associate shrinkage in this area with depression, Alzheimer’s disease and post-traumatic stress disorder.

This is not about extreme or clinical drug use. The MDMA users in this study were recreational users, the kind who take ecstasy at weekends in clubs and at festivals. Yet their hippocampal volumes shrank to a statistically and clinically meaningful degree.

The scale of the problem is worth noting. According to the European Drug Report 2024, ecstasy remains popular across Europe, particularly among young adults aged 15 to 34. In the UK, surveys consistently place it among the top five most widely used recreational drugs. A separate prospective study found that even low cumulative MDMA use produced verbal memory declines in previously drug-naive individuals, with deterioration measurable within 12 months of first use.

Limitations and What Comes Next

The study’s cross-sectional design means researchers captured a single point in time rather than tracking individuals before and after MDMA use began. They could not fully rule out pre-existing differences between groups, though the careful matching process and dose-response findings make that explanation less convincing.

MDMA users also consumed more alcohol, tobacco and cannabis than controls. The researchers controlled for those factors statistically and confirmed that stimulant co-use did not account for the grey matter findings.

The team used population-level serotonin receptor atlases rather than individual PET scans. That approach has broad acceptance in the field but does limit what researchers can say about any single person’s brain chemistry.

A longitudinal study tracking brain structure over time in new MDMA users would be the logical and powerful next step.

The Takeaway on Ecstasy Memory Loss

The evidence keeps pointing in the same direction. Ecstasy memory loss is not a myth, an exaggeration or a side effect of polydrug use. It is a measurable, dose-dependent consequence of taking MDMA, one that roots itself in the drug’s disruption of the serotonin system and its lasting impact on brain structure.

For anyone weighing the risks of recreational use, the neuroscience is increasingly difficult to dismiss. The MDMA brain damage these scans reveal is real. It scales with how much you take. And it targets the very regions the brain relies on to learn, remember and function each day.

(Source: WRD News (Brain))

Details

Published: 08 April 2026

Hits: 169

A major scientific review has concluded that e-cigarettes are likely to cause cancer. The finding could reshape how governments, health bodies and the public think about vaping. Published in the journal Carcinogenesis on 31 March 2026, the study offers one of the most comprehensive assessments of the e-cigarette cancer risk to date. It raises serious questions about a product long marketed as a safer alternative to smoking.

What the Review Found About E-Cigarette Cancer Risk

Professor Bernard Stewart, a cancer researcher at the University of New South Wales (UNSW) in Sydney, led the review. His team examined a wide body of evidence including clinical data, animal studies and laboratory experiments. The central finding was stark: nicotine-based vapes are “likely to be carcinogenic to humans.”

“Considering all the findings, from clinical monitoring, animal studies and mechanistic data, e-cigarettes are likely to cause lung cancer and oral cancer,” Professor Stewart said during a media briefing.

Many previous studies evaluated vaping only by comparing it with cigarette smoking. This review assessed the e-cigarette cancer risk on its own terms. That distinction matters. For years, the harm reduction argument has driven public health policy on vaping. This research challenges that framing directly.

The Science Linking Vaping and Cancer

E-cigarettes have only been in widespread use for around 20 years. Long-term population studies simply do not exist yet. Rather than waiting decades for that data, researchers examined biomarkers, the early biological changes that signal cancer development.

Studies in the review show that people who vape absorb nicotine-related compounds, heavy metals and other chemicals. These substances damage DNA and trigger inflammation, both of which drive cancer.

Animal studies add further weight to the concern. In one experiment, mice exposed to e-cigarette aerosols developed lung tumours at significantly higher rates than control groups. They also showed bladder changes linked to cancer.

“There is no doubt that the cells and tissues of the oral cavity and the lungs are altered by inhalation from e-cigarettes,” Professor Stewart said.

Dual Use Is Compounding the Vaping and Cancer Threat

Researchers call it “dual use.” It describes the pattern where people use both e-cigarettes and traditional cigarettes rather than fully switching. More than half of users studied could not quit either habit.

Co-author Professor Freddy Sitas, an epidemiologist at UNSW, highlighted data from the United States. People who both vape and smoke face a fourfold increased risk of developing lung cancer compared with those who do neither.

The global vaping industry is worth an estimated $30 billion to $46 billion. Major tobacco companies including Altria Group, British American Tobacco and Imperial Brands have invested heavily in e-cigarettes. For those companies, these findings carry significant commercial and regulatory weight.

A Warning From History

The review draws an uncomfortable parallel with the history of tobacco research. Scientists took decades to prove conclusively that cigarette smoking causes lung cancer. Early warning signs existed long before the field reached consensus. The authors argue researchers should not repeat this mistake with vaping and cancer.

“We should not wait another 80 years to decide what to do,” Professor Sitas said.

The concern grows sharper given how quickly vaping has spread among young people. A generation is now growing up with the habit. The long-term consequences remain unknown.

What E-Cigarette Cancer Risk Means for Public Health

Countries including New Zealand and the United Kingdom have actively encouraged smokers to switch to vaping. The new analysis questions whether those approaches adequately account for the long-term vaping and cancer relationship.

Health experts involved in the study were clear on one point. Their findings should not push smokers back to cigarettes, which remain far more harmful.

“We have always assumed that vapes are safer than cigarettes, but what we are showing is that they might not be safe after all,” Professor Sitas said.

The assessment remains qualitative. Researchers have not yet produced a numerical estimate of cancer risk. Even so, reviews over the past decade have moved steadily from uncertainty toward serious concern about carcinogenic effects.

The Bottom Line

The e-cigarette cancer risk is real, even if scientists cannot yet put a precise number on it. The idea that vaping carries no meaningful health consequences has always rested more on a lack of evidence than on proof of safety.

This review brings the long-term consequences of vaping into sharper focus. Governments, regulators and individuals now face a clear question. Act on the evidence now, or wait for certainty that may arrive too late.

(Source: WRD News)